青青操视频播放,青久精品视频免费

Sanofi Full Year 2025 Financial Report Sanofi Sanofi's 2025 results show a 9.9% revenue growth to €43.63 billion, driven by strong sales of Dupixent and new product launches. The company also achieved significant R&D breakthroughs, strategic investments, and continued commitment to sustainability.
2025 H1 Global Pharma Earnings Panorama Financial statements A comprehensive analysis of global pharma earnings in H1 2025, highlighting innovation-driven growth, key players like Novartis, Novo Nordisk, AstraZeneca, Sanofi, and BeiGene, and trends shaping the industry’s future.
Sanofi 2025 h1 Performance Sanofi Sanofi reports strong 2025 H1 results with $21.8B revenue (+9.9%), driven by Dupixent sales hitting $8B and RSV antibody Beyfortus growing 79%. Rare disease drugs and BD deals also highlight growth momentum.
Sanofi 2025 q2 Performance Sanofi Sanofi reports q2 2025 revenue of $21.9B, with Dupixent sales reaching $8B. Strong growth in immunology, vaccines, and new product launches. U.S. leads regional sales. Strategic acquisitions continue.
Sanofi and Gilead Expand Protein Degrader Portfolios Sanofi Sanofi and Gilead deepen their partnerships with Kymera Therapeutics, focusing on next-gen protein degraders for cancer and immune diseases in multi-million dollar deals, signaling rising industry interest.
Sanofi Strengthens STAT6 Pipeline with Nurix Sanofi Sanofi expands its collaboration with Nurix by licensing NX-3911, a potent STAT6 degrader targeting inflammatory diseases. The deal includes $15M upfront and up to $465M in milestones, with Nurix retaining U.S. co-development rights.
Sanofi Acquires Vigil Neuroscience for $470M Sanofi Sanofi acquires Vigil Neuroscience for $470M upfront, aiming to advance Alzheimer’s research with TREM2-targeting drug VG-3927. The deal may reach $600M with milestones and strengthens Sanofi’s neurology pipeline.
Sanofi Acquires Oral Alzheimer’s Drug VG-3927 for $470M Sanofi Sanofi acquires Vigil Neuroscience for $470M to gain rights to VG-3927, a promising once-daily oral TREM2 agonist for Alzheimer’s. The deal boosts Sanofi's position in neurodegenerative disease treatment innovation.
Sanofi's Q1 2025 Financial report Sanofi Sanofi's Q1 2025 report shows a 9.7% sales growth, driven by Dupixent and innovative drugs. The company confirms full-year guidance with strong performance in immunology, rare diseases, and vaccines.
Sanofi: Potential Super Heavy Bomb Stumbles Sanofi Sanofi's Amlitelimab, an OX40L monoclonal antibody, stumbles in asthma trials. With a strong potential in atopic dermatitis, this drug faces competition from Dupixent. OX40's future in autoimmune diseases remains promising despite challenges.

<Pre12 3 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水